Quince Therapeutics Inc (QNCX)

$1.61 -0.01 (-0.31%)
Market Cap 86.48M
Revenue (ttm) 0.00
Net Income (ttm) -56.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.45
Volume 133,800
Avg Vol 208,472
Day's Range N/A - N/A
Shares Out 53.71M
Stochastic %K 56%
Beta 0.99
Analysts Strong Sell
Price Target $7.40

Company Profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an aut...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 910 5717
Address:
611 Gateway Boulevard, Suite 273, South San Francisco, United States
4o1k
4o1k Sep. 3 at 5:44 PM
$QNCX The time is near.
0 · Reply
QNCXtothemoon
QNCXtothemoon Sep. 2 at 9:33 PM
$QNCX https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-present-hc-wainwright-27th-annual-global
0 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Aug. 22 at 5:16 PM
$QNCX https://www.fiercebiotech.com/biotech/nia-backs-lighthouses-plans-explore-bacteria-related-alzheimers-49m-grant?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=5123H8669990C0Z
3 · Reply
4o1k
4o1k Aug. 15 at 7:08 PM
$QNCX time to head back to a $1.90 and beyond.
1 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 11:30 AM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
Ego1900
Ego1900 Aug. 15 at 9:14 AM
$QNCX Was it 1.90 in AH?
1 · Reply
QNCXtothemoon
QNCXtothemoon Aug. 14 at 9:33 PM
$QNCX https://ir.quincetx.com/node/9511/html
1 · Reply
ADSlay
ADSlay Aug. 14 at 8:25 PM
$QNCX Tang gone again 😂
0 · Reply
ADSlay
ADSlay Aug. 14 at 3:59 PM
$QNCX Interesting Q2 filings so far, some new folks have joined us, welcome aboard! I think huge volume other day was because of this?
0 · Reply
bullval1
bullval1 Aug. 12 at 8:06 PM
$QNCX biggest volume day in a while
1 · Reply
Latest News on QNCX
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 2 days ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 24 days ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Aug 7, 2025, 8:00 AM EDT - 4 weeks ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 16, 2025, 8:00 AM EDT - 7 weeks ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jul 10, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 18, 2025, 4:05 PM EDT - 2 months ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 3 months ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jun 3, 2025, 4:05 PM EDT - 3 months ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

May 15, 2025, 9:50 AM EDT - 4 months ago

Quince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 4 months ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 30, 2025, 4:05 PM EDT - 4 months ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Apr 3, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:05 PM EDT - 5 months ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 7, 2025, 8:00 AM EST - 7 months ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 7 months ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Feb 4, 2025, 4:05 PM EST - 7 months ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 7 months ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 7 months ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 23, 2025, 4:05 PM EST - 8 months ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:05 PM EST - 10 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 12, 2024, 4:05 PM EST - 10 months ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Nov 11, 2024, 4:05 PM EST - 10 months ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics to Participate at Upcoming Investor Conferences

Oct 14, 2024, 4:05 PM EDT - 11 months ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 19, 2024, 9:16 PM EDT - 1 year ago

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

May 6, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Launches Scientific Advisory Board

Feb 22, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 15, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quince Therapeutics to Participate at Investor Events in January 2024

Jan 4, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics to Participate at Investor Events in January 2024

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Sep 28, 2023, 4:05 PM EDT - 2 years ago

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.

Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital

Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Apr 5, 2023, 4:05 PM EDT - 2 years ago

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Mar 22, 2023, 5:00 AM EDT - 2 years ago

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.

Mar 21, 2023, 8:00 AM EDT - 2 years ago

Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.

Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

Jan 30, 2023, 4:05 PM EST - 2 years ago

Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

4o1k
4o1k Sep. 3 at 5:44 PM
$QNCX The time is near.
0 · Reply
QNCXtothemoon
QNCXtothemoon Sep. 2 at 9:33 PM
$QNCX https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-present-hc-wainwright-27th-annual-global
0 · Reply
GordonGecko_was_THE_MAN
GordonGecko_was_THE_MAN Aug. 22 at 5:16 PM
$QNCX https://www.fiercebiotech.com/biotech/nia-backs-lighthouses-plans-explore-bacteria-related-alzheimers-49m-grant?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=5123H8669990C0Z
3 · Reply
4o1k
4o1k Aug. 15 at 7:08 PM
$QNCX time to head back to a $1.90 and beyond.
1 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 11:30 AM
D. Boral Capital has adjusted their stance on Quince Therapeutics ( $QNCX ), setting the rating to Buy with a target price of 4.
0 · Reply
Ego1900
Ego1900 Aug. 15 at 9:14 AM
$QNCX Was it 1.90 in AH?
1 · Reply
QNCXtothemoon
QNCXtothemoon Aug. 14 at 9:33 PM
$QNCX https://ir.quincetx.com/node/9511/html
1 · Reply
ADSlay
ADSlay Aug. 14 at 8:25 PM
$QNCX Tang gone again 😂
0 · Reply
ADSlay
ADSlay Aug. 14 at 3:59 PM
$QNCX Interesting Q2 filings so far, some new folks have joined us, welcome aboard! I think huge volume other day was because of this?
0 · Reply
bullval1
bullval1 Aug. 12 at 8:06 PM
$QNCX biggest volume day in a while
1 · Reply
HarmonyPioneer67
HarmonyPioneer67 Aug. 12 at 6:20 PM
$QNCX
0 · Reply
InstinctInvestor
InstinctInvestor Aug. 12 at 5:46 PM
$QNCX COMIN UP ON MY ALERT
1 · Reply
Wolf_in_Street
Wolf_in_Street Aug. 12 at 5:39 PM
$QNCX News?
0 · Reply
SearchFor911
SearchFor911 Aug. 12 at 4:55 PM
$QNCX someone knows something? Large inflows
0 · Reply
Ego1900
Ego1900 Aug. 12 at 4:48 PM
$QNCX it's ready to take off
0 · Reply
4o1k
4o1k Aug. 12 at 3:52 PM
$QNCX next stop $2.00
1 · Reply
RunningRobert1
RunningRobert1 Aug. 12 at 1:19 PM
$QNCX Quince Therapeutics QNCX 2Q 2025 Summary 12Aug2025 https://youtu.be/QAXNo9ujQQo Overall fairly boring, we are expected data in Q1 2026, so with that I expect the 3rd Q Summary will also be boring, but then.....Data!
0 · Reply
d_risk
d_risk Aug. 12 at 12:37 AM
$QNCX - Quince Therapeutics, Inc. - 10Q - Updated Risk Factors QNCX warns that future stock sales could pressure share price, and put rights on outstanding warrants may complicate completing beneficial fundamental transactions. #Biotechnology #MarketVolatility #CapitalRaising #Warrants #StockPriceRisk 🟢 Added 🟠 Removed https://d-risk.ai/QNCX/10-Q/2025-08-11
0 · Reply
QNCXtothemoon
QNCXtothemoon Aug. 11 at 8:26 PM
$QNCX https://ir.quincetx.com/news-releases/news-release-details/quince-therapeutics-provides-business-update-and-reports-0
0 · Reply
4o1k
4o1k Aug. 11 at 7:00 PM
$QNCX good entry point.
0 · Reply
ADSlay
ADSlay Aug. 7 at 11:49 PM
$QNCX asked Grok basic questions: - did $OPCH conduct a thorough analysis of $QNCX? - would $OPCH still have partnered with $QNCX if it had found there was nothing in it for them after doing a thorough analysis? make what you will
0 · Reply
ADSlay
ADSlay Aug. 7 at 7:55 PM
$QNCX Now think why would such a big company want to associate with someone like QNCX? They must have researched / analyzed the prior ATTeST Ph3 data and seen something in our current Ph3 setup. 🚀🚀🚀
2 · Reply